学术探索
学术期刊
新闻热点
数据分析
智能评审

CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin:: Similarities yet differences

被引：39
作者：
Takahashi, H
Wilkinson, GR
Padrini, R
Echizen, H
机构：
[1] Meiji Pharmaceut Univ, Dept Pharmacotherapy, Tokyo 2048588, Japan
[2] Vanderbilt Univ, Div Clin Pharmacol, Sch Med, Nashville, TN USA
[3] Univ Padua, Dept Pharmacol & Anesthesiol, Padua, Italy
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2004年 / 75卷 / 05期
关键词：
D O I：
10.1016/j.clpt.2004.01.007
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：376 / 380
页数：5
相关论文
共 28 条
  • [1] Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
    Aithal, GP
    Day, CP
    Kesteven, PJL
    Daly, AK
    [J]. LANCET, 1999, 353 (9154) : 717 - 719
  • [2] BRECKENRIDGE A, 1974, CLIN PHARMACOL THER, V15, P424
  • [3] Pharmacogenetics of oral anticoagulants
    Daly, AK
    King, BP
    [J]. PHARMACOGENETICS, 2003, 13 (05): : 247 - 252
  • [4] Regulation of human CYP2C9 by the constitutive androstane receptor:: Discovery of a new distal binding site
    Ferguson, SS
    Lecluyse, EL
    Negishi, M
    Goldstein, JA
    [J]. MOLECULAR PHARMACOLOGY, 2002, 62 (03) : 737 - 746
  • [5] PHARMACOKINETICS OF THE ENANTIOMERS OF ACENOCOUMAROL IN MAN
    GODBILLON, J
    RICHARD, J
    GERARDIN, A
    MEINERTZ, T
    KASPER, W
    JAHNCHEN, E
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1981, 12 (05) : 621 - 629
  • [6] Allelic variants of human cytochrome P450 2C9: Baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms
    Haining, RL
    Hunter, AP
    Veronese, ME
    Trager, WF
    Rettie, AE
    [J]. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1996, 333 (02) : 447 - 458
  • [7] Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy
    Higashi, MK
    Veenstra, DL
    Kondo, LML
    Wittkowsky, AK
    Srinouanprachanh, SL
    Farin, FM
    Rettie, AE
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (13): : 1690 - 1698
  • [8] Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin
    Kamali, F
    Khan, TI
    King, BP
    Frearson, R
    Kesteven, P
    Wood, P
    Daly, AK
    Wynne, H
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (03) : 204 - 212
  • [9] Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers
    Kirchheiner, J
    Brockmöller, J
    Meineke, I
    Bauer, S
    Rohde, W
    Meisel, C
    Roots, I
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (04) : 286 - 296
  • [10] Interindividual variability in sensitivity to warfarin - Nature or nurture?
    Loebstein, R
    Yonath, H
    Peleg, D
    Almog, S
    Rotenberg, M
    Lubetsky, A
    Roitelman, J
    Harats, D
    Halkin, H
    Ezra, D
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 70 (02) : 159 - 164
123